189 related articles for article (PubMed ID: 35931078)
1. Characterization of N-terminal RYR2 variants outside CPVT1 hotspot regions using patient iPSCs reveal pathogenesis and therapeutic potential.
Stutzman MJ; Kim CSJ; Tester DJ; Hamrick SK; Dotzler SM; Giudicessi JR; Miotto MC; Gc JB; Frank J; Marks AR; Ackerman MJ
Stem Cell Reports; 2022 Sep; 17(9):2023-2036. PubMed ID: 35931078
[TBL] [Abstract][Full Text] [Related]
2. Calcium signaling consequences of RyR2 mutations associated with CPVT1 introduced via CRISPR/Cas9 gene editing in human-induced pluripotent stem cell-derived cardiomyocytes: Comparison of RyR2-R420Q, F2483I, and Q4201R.
Zhang XH; Wei H; Xia Y; Morad M
Heart Rhythm; 2021 Feb; 18(2):250-260. PubMed ID: 32931925
[TBL] [Abstract][Full Text] [Related]
3. Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations.
Novak A; Barad L; Lorber A; Gherghiceanu M; Reiter I; Eisen B; Eldor L; Itskovitz-Eldor J; Eldar M; Arad M; Binah O
J Cell Mol Med; 2015 Aug; 19(8):2006-18. PubMed ID: 26153920
[TBL] [Abstract][Full Text] [Related]
4. A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses.
Preininger MK; Jha R; Maxwell JT; Wu Q; Singh M; Wang B; Dalal A; Mceachin ZT; Rossoll W; Hales CM; Fischbach PS; Wagner MB; Xu C
Dis Model Mech; 2016 Sep; 9(9):927-39. PubMed ID: 27491078
[TBL] [Abstract][Full Text] [Related]
5. Novel Calmodulin Variant p.E46K Associated With Severe Catecholaminergic Polymorphic Ventricular Tachycardia Produces Robust Arrhythmogenicity in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Gao J; Makiyama T; Yamamoto Y; Kobayashi T; Aoki H; Maurissen TL; Wuriyanghai Y; Kashiwa A; Imamura T; Aizawa T; Huang H; Kohjitani H; Nishikawa M; Chonabayashi K; Fukuyama M; Manabe H; Nakau K; Wada T; Kato K; Toyoda F; Yoshida Y; Makita N; Woltjen K; Ohno S; Kurebayashi N; Murayama T; Sakurai T; Horie M; Kimura T
Circ Arrhythm Electrophysiol; 2023 Mar; 16(3):e011387. PubMed ID: 36866681
[TBL] [Abstract][Full Text] [Related]
6. Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models.
Penttinen K; Swan H; Vanninen S; Paavola J; Lahtinen AM; Kontula K; Aalto-Setälä K
PLoS One; 2015; 10(5):e0125366. PubMed ID: 25955245
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of the calcium release channel deficiency syndrome.
Tester DJ; Kim CSJ; Hamrick SK; Ye D; O'Hare BJ; Bombei HM; Fitzgerald KK; Haglund-Turnquist CM; Atkins DL; Nunez LAO; Law I; Temple J; Ackerman MJ
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32663189
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9 Gene Editing of RYR2 in Human iPSC-Derived Cardiomyocytes to Probe Ca
Yamaguchi N; Zhang XH; Morad M
Methods Mol Biol; 2022; 2573():41-52. PubMed ID: 36040585
[TBL] [Abstract][Full Text] [Related]
9. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells.
Itzhaki I; Maizels L; Huber I; Gepstein A; Arbel G; Caspi O; Miller L; Belhassen B; Nof E; Glikson M; Gepstein L
J Am Coll Cardiol; 2012 Sep; 60(11):990-1000. PubMed ID: 22749309
[TBL] [Abstract][Full Text] [Related]
10. In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells.
Fatima A; Xu G; Shao K; Papadopoulos S; Lehmann M; Arnáiz-Cot JJ; Rosa AO; Nguemo F; Matzkies M; Dittmann S; Stone SL; Linke M; Zechner U; Beyer V; Hennies HC; Rosenkranz S; Klauke B; Parwani AS; Haverkamp W; Pfitzer G; Farr M; Cleemann L; Morad M; Milting H; Hescheler J; Saric T
Cell Physiol Biochem; 2011; 28(4):579-92. PubMed ID: 22178870
[TBL] [Abstract][Full Text] [Related]
11. Mutation-specific differences in arrhythmias and drug responses in CPVT patients: simultaneous patch clamp and video imaging of iPSC derived cardiomyocytes.
Pölönen RP; Swan H; Aalto-Setälä K
Mol Biol Rep; 2020 Feb; 47(2):1067-1077. PubMed ID: 31786768
[TBL] [Abstract][Full Text] [Related]
12. CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia.
Di Pasquale E; Lodola F; Miragoli M; Denegri M; Avelino-Cruz JE; Buonocore M; Nakahama H; Portararo P; Bloise R; Napolitano C; Condorelli G; Priori SG
Cell Death Dis; 2013 Oct; 4(10):e843. PubMed ID: 24113177
[TBL] [Abstract][Full Text] [Related]
13. Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations.
Kujala K; Paavola J; Lahti A; Larsson K; Pekkanen-Mattila M; Viitasalo M; Lahtinen AM; Toivonen L; Kontula K; Swan H; Laine M; Silvennoinen O; Aalto-Setälä K
PLoS One; 2012; 7(9):e44660. PubMed ID: 22962621
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of RyR2 inhibitor EL20 in induced pluripotent stem cell-derived cardiomyocytes from a patient with catecholaminergic polymorphic ventricular tachycardia.
Word TA; Quick AP; Miyake CY; Shak MK; Pan X; Kim JJ; Allen HD; Sibrian-Vazquez M; Strongin RM; Landstrom AP; Wehrens XHT
J Cell Mol Med; 2021 Jun; 25(13):6115-24. PubMed ID: 34110090
[TBL] [Abstract][Full Text] [Related]
15. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia.
Jung CB; Moretti A; Mederos y Schnitzler M; Iop L; Storch U; Bellin M; Dorn T; Ruppenthal S; Pfeiffer S; Goedel A; Dirschinger RJ; Seyfarth M; Lam JT; Sinnecker D; Gudermann T; Lipp P; Laugwitz KL
EMBO Mol Med; 2012 Mar; 4(3):180-91. PubMed ID: 22174035
[TBL] [Abstract][Full Text] [Related]
16. The V2475F CPVT1 mutation yields distinct RyR2 channel populations that differ in their responses to cytosolic Ca
Wilson AD; Hu J; Sigalas C; Venturi E; Valdivia HH; Valdivia CR; Lei M; Musgaard M; Sitsapesan R
J Physiol; 2021 Dec; 599(23):5179-5201. PubMed ID: 34676560
[TBL] [Abstract][Full Text] [Related]
17. Ca2+ signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects.
Zhang XH; Haviland S; Wei H; Sarić T; Fatima A; Hescheler J; Cleemann L; Morad M
Cell Calcium; 2013 Aug; 54(2):57-70. PubMed ID: 23684427
[TBL] [Abstract][Full Text] [Related]
18. The oxidation-resistant CaMKII-MM281/282VV mutation does not prevent arrhythmias in CPVT1.
Sadredini M; Manotheepan R; Lehnart SE; Anderson ME; Sjaastad I; Stokke MK
Physiol Rep; 2021 Sep; 9(18):e15030. PubMed ID: 34558218
[TBL] [Abstract][Full Text] [Related]
19. Z16b, a natural compound from Ganoderma cochlear is a novel RyR2 stabilizer preventing catecholaminergic polymorphic ventricular tachycardia.
Wan JF; Wang G; Qin FY; Huang DL; Wang Y; Su AL; Zhang HP; Liu Y; Zeng SY; Wei CL; Cheng YX; Liu J
Acta Pharmacol Sin; 2022 Sep; 43(9):2340-2350. PubMed ID: 35190699
[TBL] [Abstract][Full Text] [Related]
20. Personalized medicine in the dish to prevent calcium leak associated with short-coupled polymorphic ventricular tachycardia in patient-derived cardiomyocytes.
Sleiman Y; Reiken S; Charrabi A; Jaffré F; Sittenfeld LR; Pasquié JL; Colombani S; Lerman BB; Chen S; Marks AR; Cheung JW; Evans T; Lacampagne A; Meli AC
Stem Cell Res Ther; 2023 Sep; 14(1):266. PubMed ID: 37740238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]